Search

Your search keyword '"Donson, Andrew M."' showing total 421 results

Search Constraints

Start Over You searched for: Author "Donson, Andrew M." Remove constraint Author: "Donson, Andrew M."
421 results on '"Donson, Andrew M."'

Search Results

3. Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature

4. Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas

5. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas

7. Multi-pronged analysis of pediatric low-grade glioma reveals a unique tumor microenvironment associated with BRAF alterations

8. Targeting fibroblast growth factor receptors to combat aggressive ependymoma

9. Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma

10. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis

11. SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups

12. Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B

15. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

18. Genetic Predictors of Neurocognitive Outcomes in Survivors of Pediatric Brain Tumors

19. Mapping pediatric brain tumors to their origins in the developing cerebellum

20. Robust deep learning classification of adamantinomatous craniopharyngioma from limited preoperative radiographic images

21. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target

22. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study

23. Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas

25. Supplementary Table S4 from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas

28. Supplemental Figure Legends from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

30. Supplementary Figure 5 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

32. Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

33. Data from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

34. Supplementary Data from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

35. Supplementary Figure 6 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

36. Supplementary Figure 1 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

37. Supplementary Figure 2 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

40. Supplementary figure 1 from Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

41. Supplementary Figure 4 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

42. Supplementary Table 1 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

43. Supplementary Figure 2 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

44. Supplementary Data from Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion–Positive Supratentorial Ependymomas

46. Supplementary Figure 3 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma

48. Supplementary Data from Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity

50. Spatial transcriptomic analysis delineates epithelial and mesenchymal subpopulations and transition stages in childhood ependymoma

Catalog

Books, media, physical & digital resources